Post myocardial infarction patients are usually started on high intensity statin Rx. Followup in office will include following lipid panel. Insurance carrier permitting, an injectable lipid lowering medication can be added if LDL is not below 55, but usually insurance only permits addition of injectables if LDL remains above 70 on high intensity...
Expert opinion on the integration of combination therapy into the treatment algorithm for the management of dyslipidaemia: the integration of ezetimibe and bempedoic acid may enhance goal attainment - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/40052330/
The clinically important link between LDL cholesterol (LDL - C) lowering and cardiovascular (CV) risk reduction is well-established and reflected in the 2019 European Society of Cardiology/European Atherosclerosis Society guidelines...
Expert consensus highlights LDL-C goal gaps in practice, recommending upfront combination lipid-lowering therapy, including novel agents like bempedoic acid, for high/very high cardiovascular risk and statin-intolerant patients.
